Hie-Won Hann

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentMedicine
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8900
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Katcher JG, Klassen AC, Hann HW, Chang M, Juon HS. Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B-related stigma among patients with chronic hepatitis B. J Viral Hepat. 2024 Feb 26. PMID: 38409935.
      Citations:    
    2. Varghese N, Majeed A, Nyalakonda S, Boortalary T, Halegoua-DeMarzio D, Hann HW. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cancers (Basel). 2024 Feb 14; 16(4). PMID: 38398168.
      Citations:    
    3. Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Rep. 2024 Apr; 6(4):100999. PMID: 38510983.
      Citations:    
    4. Lin SY, Xia W, Kim AK, Chen D, Schleyer S, Choi L, Wang Z, Hamilton JP, Luu H, Hann HW, Chang TT, Hu CT, Woodard A, Gade TP, Su YH. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma. Sci Rep. 2023 12 07; 13(1):21585. PMID: 38062093.
      Citations:    
    5. Fung SK, Pan CQ, Wong GL, Seto WK, Ahn SH, Chen CY, Hann HL, Jablkowski MS, Kim YJ, Yurdaydin C, Peng CY, Nguyen T, Yatsuhashi H, Flaherty JF, Yee LJ, Abramov F, Wang H, Abdurakhmanov D, Lim YS, Buti M. Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96?weeks. Aliment Pharmacol Ther. 2023 Oct 31. PMID: 37905449.
      Citations:    
    6. Lin D, Luo R, Ye Z, Wei Q, Bae H, Juon HS, Hann HW, Posey J, Wang C. Genomic characterization of early-stage hepatocellular carcinoma patients with Hepatitis B using circulating tumor DNA. Clin Res Hepatol Gastroenterol. 2023 Jun 10; 47(7):102161. PMID: 37307947.
      Citations:    
    7. Lin SY, Halegoua-DeMarzio D, Block P, Kao YL, Civan J, Shieh FS, Song W, Hann HW, Su YH. Persistently Elevated HBV Viral-Host Junction DNA in Urine as a Biomarker for Hepatocellular Carcinoma Minimum Residual Disease and Recurrence: A Pilot Study. Diagnostics (Basel). 2023 Apr 25; 13(9). PMID: 37174929.
      Citations:    
    8. Noverati N, Nguyen A, Chalikonda D, Halegoua-DeMarzio D, Hann HW. The Role of Host in the Spectrum of Outcomes in Family Clusters of Hepatitis Infection: From Asymptomatic to Hepatocellular Carcinoma. Case Rep Gastroenterol. 2023 Jan-Dec; 17(1):104-110. PMID: 36818365.
      Citations:    
    9. Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Yuen MF. Safety and efficacy of vebicorvir administered with entecavir in treatment-na?ve patients with chronic hepatitis B virus infection. J Hepatol. 2022 11; 77(5):1265-1275. PMID: 35697332.
      Citations:    
    10. Pan CQ, Afdhal NH, Ankoma-Sey V, Bae H, Curry MP, Dieterich D, Frazier L, Frick A, Hann HW, Kim WR, Kwo P, Milligan S, Tong MJ, Reddy KR. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide. Hepatol Commun. 2022 08; 6(8):1881-1894. PMID: 35445803.
      Citations:    
    11. Yuen MF, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HL, Dieterich DT, Nahass RG, Park JS, Chan S, Han SB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, Knox SJ, Stamm LM, Bonacini M, Jacobson IM, Ayoub WS, Weilert F, Ravendhran N, Ramji A, Kwo PY, Elkhashab M, Hassanein T, Bae HS, Lalezari JP, Fung SK, Sulkowski MS. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J Hepatol. 2022 09; 77(3):642-652. PMID: 35460726.
      Citations:    
    12. Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-Fetoprotein (AFP) and AFP-L3 Is Most Useful in Detection of Recurrence of Hepatocellular Carcinoma in Patients after Tumor Ablation and with Low AFP Level. Viruses. 2022 04 08; 14(4). PMID: 35458505.
      Citations:    
    13. Noverati N, Bashir-Hamidu R, Halegoua-DeMarzio D, Hann HW. Hepatitis B Virus-Associated Hepatocellular Carcinoma and Chronic Stress. Int J Mol Sci. 2022 Apr 01; 23(7). PMID: 35409275.
      Citations:    
    14. Kim AK, Hamilton JP, Lin SY, Chang TT, Hann HW, Hu CT, Lou Y, Lin YJ, Gade TP, Park G, Luu H, Lee TJ, Wang J, Chen D, Goggins MG, Jain S, Song W, Su YH. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022 06; 126(10):1432-1438. PMID: 35046521.
      Citations:    
    15. Lin SY, Su YP, Trauger ER, Song BP, Thompson EGC, Hoffman MC, Chang TT, Lin YJ, Kao YL, Cui Y, Hann HW, Park G, Shieh FS, Song W, Su YH. Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected Patients. Hepatol Commun. 2021 10; 5(10):1649-1659. PMID: 34558837.
      Citations:    
    16. Bashir Hamidu R, Chalikonda DM, Hann HW. Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines (Basel). 2021 Jul 30; 9(8). PMID: 34451963.
      Citations:    
    17. Block PD, Shinn B, Kim JH, Hann HW. Hepatitis B-related hepatocellular carcinoma and stress: untangling the host immune response from clinical outcomes. Hepat Oncol. 2020 Dec 29; 8(1):HEP35. PMID: 33680431.
      Citations:    
    18. Hou JL, Zhao W, Lee C, Hann HW, Peng CY, Tanwandee T, Morozov V, Klinker H, Sollano JD, Streinu-Cercel A, Cheinquer H, Xie Q, Wang YM, Wei L, Jia JD, Gong G, Han KH, Cao W, Cheng M, Tang X, Tan D, Ren H, Duan Z, Tang H, Gao Z, Chen S, Lin S, Sheng J, Chen C, Shang J, Han T, Ji Y, Niu J, Sun J, Chen Y, Cooney EL, Lim SG. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. Clin Gastroenterol Hepatol. 2020 02; 18(2):457-467.e21. PMID: 31306800.
      Citations:    
    19. Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol. 2019 Jan 27; 11(1):65-73. PMID: 30705719.
      Citations:    
    20. Bian Z, Hann HW, Ye Z, Yin C, Wang Y, Fang W, Wan S, Wang C, Tao K. Ferritin level prospectively predicts hepatocarcinogenesis in patients with chronic hepatitis B virus infection. Oncol Lett. 2018 Sep; 16(3):3499-3508. PMID: 30127954.
      Citations:    
    21. Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018 Apr 20; 6(2). PMID: 29677098.
      Citations:    
    22. Hann HW, Jain S, Park G, Steffen JD, Song W, Su YH. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017; 3:105-111. PMID: 28795155.
      Citations:    
    23. Wan S, Hann HW, Ye Z, Hann RS, Lai Y, Wang C, Li L, Myers RE, Li B, Xing J, Yang H. Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis. 2017 Apr 01; 38(4):439-446. PMID: 28334112.
      Citations:    
    24. Dargan A, Wong SY, Coben R, Conn M, Dimarino AJ, Hann HW. Persistent risk for hepatocellular carcinoma after more than a decade of successful hepatitis B virus suppression. Minerva Gastroenterol Dietol. 2017 Mar; 63(1):74-76. PMID: 28054479.
      Citations:    
    25. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Kim K, Kitrinos KM, Subramanian GM, McHutchison JG, Yee LJ, Elkhashab M, Berg T, Sporea I, Yurdaydin C, Husa P, Jablkowski MS, Gane E. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017 01; 66(1):11-18. PMID: 27545497.
      Citations:    
    26. Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy KR, Trinh H, Chu D, Tran T, Lau D, Leduc TS, Min A, Trong Le L, Bae H, Van Tran S, Do S, Hann HW, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim WR. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study. Am J Gastroenterol. 2016 09; 111(9):1297-304. PMID: 27325221.
      Citations:    
    27. Li L, Hann HW, Wan S, Hann RS, Wang C, Lai Y, Ye X, Evans A, Myers RE, Ye Z, Li B, Xing J, Yang H. Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection. Sci Rep. 2016; 6:23992. PMID: 27063412.
      Citations:    
    28. Wang M, Devarajan K, Singal AG, Marrero JA, Dai J, Feng Z, Rinaudo JA, Srivastava S, Evans A, Hann HW, Lai Y, Yang H, Block TM, Mehta A. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. Cancer Prev Res (Phila). 2016 Feb; 9(2):172-9. PMID: 26712941.
      Citations:    
    29. Civan J, Hann HW. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough? Expert Opin Drug Saf. 2015 Jun; 14(6):865-75. PMID: 25826452.
      Citations:    
    30. Wang C, Hann HW, Hann RS, Wan S, Myers RE, Ye Z, Xing J, Yang H. Circulating mitochondrial DNA content associated with the risk of liver cirrhosis: a nested case-control study. Dig Dis Sci. 2015 Jun; 60(6):1707-15. PMID: 25588520.
      Citations:    
    31. Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, Zhang K, Ye Z, Wang C, Yang H. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2015 Jan; 30(1):131-8. PMID: 24995497.
      Citations:    
    32. Hann HW. Advances in the management of hepatitis B virus infection. Gastroenterol Hepatol (N Y). 2014 Jun; 10(6):384-6. PMID: 25013391.
      Citations:    
    33. Hann HW, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann RS, Park KB, Dunn S, Dimarino AJ. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014 Apr; 3(2):390-6. PMID: 24519810.
      Citations:    
    34. Halegoua-De Marzio D, Hann HW. Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol. 2014 Jan 14; 20(2):401-13. PMID: 24574709.
      Citations:    
    35. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B, Dinh P, Corsa A, Subramanian GM, McHutchison JG, Husa P, Gane E. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014 Apr; 146(4):980-8. PMID: 24368224.
      Citations:    
    36. Lee H, Kiang P, Chea P, Peou S, Tang SS, Yang J, Fawcett J, Hann HW. HBV-related health behaviors in a socio-cultural context: perspectives from Khmers and Koreans. Appl Nurs Res. 2014 May; 27(2):127-32. PMID: 24355416.
      Citations:    
    37. Petruzzi NJ, Frangos AJ, Fenkel JM, Herrine SK, Hann HW, Rossi S, Rosato EL, Eschelman DJ, Gonsalves CF, Brown DB. Single-center Comparison of Three Chemoembolization Regimens for Hepatocellular Carcinoma. J Vasc Interv Radiol. 2013 Feb; 24(2):266-73. PMID: 23261143.
      Citations:    
    38. Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, Yang H. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One. 2012; 7(10):e47687. PMID: 23112834.
      Citations:    
    39. Lee H, Fawcett J, Yang JH, Hann HW. Correlates of hepatitis B virus health-related behaviors of Korean Americans: a situation-specific nursing theory. J Nurs Scholarsh. 2012 Dec; 44(4):315-22. PMID: 23057710.
      Citations:    
    40. Wan S, Hann HW, Myers RE, Fu X, Hann RS, Kim SH, Tang H, Xing J, Yang H. Telomere length in circulating serum DNA as a novel non-invasive biomarker for cirrhosis: a nested case-control analysis. Liver Int. 2012 Sep; 32(8):1233-41. PMID: 22471856.
      Citations:    
    41. Fu X, Wan S, Hann HW, Myers RE, Hann RS, Au J, Chen B, Xing J, Yang H. Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection. Eur J Cancer. 2012 May; 48(7):1014-22. PMID: 22444598.
      Citations:    
    42. Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, Au N, Xing J, Yang H. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection--results from a clinic-based longitudinal cohort. Eur J Cancer. 2012 Oct; 48(15):2319-27. PMID: 22436980.
      Citations:    
    43. Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The management of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011 Nov; 56(11):3143-62. PMID: 21935699.
      Citations:    
    44. Lee H, Hann HW, Yang JH, Fawcett J. Recognition and management of HBV infection in a social context. J Cancer Educ. 2011 Sep; 26(3):516-21. PMID: 21347651.
      Citations:    
    45. Hann HW, Bergin D, Coben R, DiMarino AJ. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated. Int J Cancer. 2011 Feb 1; 128(3):739-42. PMID: 20473872.
      Citations:    
    46. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011 Jun; 5(2):654-63. PMID: 21484148.
      Citations:    
    47. Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother. 2010 Sep; 11(13):2243-9. PMID: 20698726.
      Citations:    
    48. Hann HW, Dunn SR, Ahn M, Park SY. Question of ALT flare during switch to adefovir from lamivudine: A single center open-label, randomized, safety study (June 17, 2005 to February 5, 2009). J Med Virol. 2010 Sep; 82(9):1489-93. PMID: 20648601.
      Citations:    
    49. Hann HW, Wang M, Hafner J, Long RE, Kim SH, Ahn M, Park S, Comunale MA, Block TM, Mehta A. Analysis of GP73 in patients with HCC as a function of anti-cancer treatment. Cancer Biomark. 2010; 7(6):269-73. PMID: 21694465.
      Citations:    
    50. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009 Jan; 49(1):72-9. PMID: 19065670.
      Citations:    
    51. Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int. 2008 Dec; 2(4):440-56. PMID: 19669319.
      Citations:    
    52. Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008 Jun; 2(2):244-9. PMID: 19669311.
      Citations:    
    53. Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol. 2007 Aug 14; 13(30):4085-90. PMID: 17696226.
      Citations:    
    54. Choi D, Mitchell DG, Verma SK, Bergin D, Navarro VJ, Malliah AB, McGowan C, Hann HW, Herrine SK. Hepatocellular carcinoma with indeterminate or false-negative findings at initial MR imaging: effect on eligibility for curative treatment initial observations. Radiology. 2007 Sep; 244(3):776-83. PMID: 17690322.
      Citations:    
    55. Chae HB, Hann HW. Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection. Ther Clin Risk Manag. 2007 Aug; 3(4):605-12. PMID: 18472982.
      Citations:    
    56. Hann HW, Hann RS, Maddrey WC. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol. 2007 Apr; 102(4):767-72. PMID: 17397407.
      Citations:    
    57. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, Seeholzer S, Evans AA, Hann HW, Block TM, Mehta AS. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006 Feb; 5(2):308-15. PMID: 16457596.
      Citations:    
    58. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 Aug; 129(2):528-36. PMID: 16083710.
      Citations:    
    59. Hann HW, Jonsson Funk ML, Rosenberg DM, Davis R. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol. 2005 Mar; 20(3):433-40. PMID: 15740489.
      Citations:    
    60. Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K, Clayton MM, Ardlie K, Pellini MJ, Feitelson MA. Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res. 2004 Oct 15; 64(20):7329-35. PMID: 15492253.
      Citations:    
    61. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90. PMID: 14699490.
      Citations:    
    62. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56. PMID: 12514773.
      Citations:    
    63. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002 Sep; 123(3):719-27. PMID: 12198698.
      Citations:    
    64. Hann HW. Prevention and Treatment of Primary Hepatocellular Carcinoma in Asian Americans. Asian Am Pac Isl J Health. 1998; 6(2):292-301. PMID: 11567453.
      Citations:    
    Hann's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (151)
    Explore
    _
    Co-Authors (25)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _